Loading
A phase 1/2 trial of AK117 and Azacitidine in acute myeloid leukaemia, run by Akeso, active and no longer recruiting.
A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia is a phase 1/2 interventional study registered as NCT04980885 by Akeso, with 68 participants enrolled, started 2021-08-13 and due to reach its primary completion in 2025-09. Interventions recorded: AK117 and Azacitidine.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares AK117, Tumour-associated macrophages (TAMs), Akeso and the tag pipeline.
Shares AK117, Tumour-associated macrophages (TAMs), Akeso and the tag pipeline.
Shares Tumour-associated macrophages (TAMs), Azacitidine, Acute myeloid leukaemia and the tag pipeline.
Shares Tumour-associated macrophages (TAMs), Azacitidine, Acute myeloid leukaemia and the tag pipeline.
Shares Tumour-associated macrophages (TAMs), Akeso and the tag pipeline.
Shares Azacitidine, Acute myeloid leukaemia and the tag pipeline.
Shares Azacitidine, Acute myeloid leukaemia and the tag pipeline.
Shares Tumour-associated macrophages (TAMs), Azacitidine and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/